Genmab A/S (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Genmab A/S (NASDAQ:GMAB - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $39.17.

GMAB has been the topic of several research analyst reports. Truist Financial dropped their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research report on Thursday, February 13th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Finally, Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its stake in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC raised its stake in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC raised its stake in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC raised its stake in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC raised its stake in Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after purchasing an additional 2,496 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Price Performance

GMAB stock traded up $0.16 during midday trading on Thursday, hitting $20.79. 1,230,981 shares of the stock traded hands, compared to its average volume of 1,053,486. The firm has a market cap of $13.76 billion, a P/E ratio of 11.95, a PEG ratio of 2.65 and a beta of 1.07. The stock's fifty day simple moving average is $20.41 and its 200-day simple moving average is $21.00. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, research analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.